We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Rigel Gears Up to Report Q3 Earnings: Here's What to Expect
Read MoreHide Full Article
Key Takeaways
Rigel will report Q3 2025 earnings on Nov. 4, with revenue estimated at $61.6 million.
Tavalisse demand and solid sales of Rezlidhia and Gavreto are likely to have driven RIGL's revenue growth.
Investors await updates on R289 and potential new guidance amid strong product momentum.
Rigel Pharmaceuticals (RIGL - Free Report) is scheduled to report third-quarter 2025 results on Nov. 4, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $61.6 million, while the same for earnings is 93 cents per share.
Let’s see how things might have shaped up before the announcement.
Factors Shaping RIGL's Q3 Results
Rigel records revenues primarily from the sale of its marketed products and contract revenues from collaborations.
The majority of the company’s revenue growth in the third quarter is likely to have been driven by the robust uptake of its lead product, Tavalisse, which is approved for treating chronic immune thrombocytopenia (“ITP”).
Tavalisse sales are being driven by continued strong new patient demand and the momentum is expected to have continued in the third quarter.
Besides Tavalisse, Rigel is also making good progress with its other marketed products, Rezlidhia (olutasidenib) and Gavreto (pralsetinib), which are approved for treating certain cancer indications. Incremental sales from both these drugs are likely to have boosted Rigel’s top line in the to-be-reported quarter.
Year to date, shares of Rigel have surged 88% compared with the industry’s rise of 7.3%.
Image Source: Zacks Investment Research
Rigel has R289 in its pipeline, a novel dual IRAK1 and IRAK4 inhibitor, in an early-stage study for treating patients with lower-risk myelodysplastic syndrome (MDS). The company is also exploring Rezlidhia’s (olutasidenib) use beyond the approved indication of relapsed or refractory IDH1-mutated AML into other cancers with IDH1 mutations, such as recurrent glioma. Updates related to these activities are expected on the upcoming earnings call.
Higher research and development expenses, as well as increased selling and general and administrative costs, are likely to have escalated operating expenses in the third quarter.
RIGL’s Earnings Surprise History
Rigel has an encouraging history of earnings surprises. The company beat on earnings in each of the trailing four quarters, delivering an average surprise of 1,840.49%. In the last reported quarter, RIGL delivered an earnings surprise of 66.50%.
What Our Model Predicts for RIGL
Our proven model does not conclusively predict an earnings beat for Rigel this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here.
Earnings ESP: Rigel’s Earnings ESP is 0.00%, as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at 93 cents per share. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are some drug/biotech stocks that have the right combination of elements to beat on earnings this time around:
Exact Sciences (EXAS - Free Report) has an Earnings ESP of +20.00% and sports a Zacks Rank #1 at present.
Shares of EXAS have increased 12.5% year to date. EXAS beat on earnings in three of the trailing four quarters and missed in one, delivering an average surprise of 329.87%. Exact Sciences is scheduled to report third-quarter results on Nov. 3.
ANI Pharmaceuticals (ANIP - Free Report) has an Earnings ESP of +10.55% and a Zacks Rank #2.
ANI Pharmaceuticals’ stock has risen 66.3% so far this year. ANIP beat earnings estimates in each of the last four reported quarters, delivering an earnings surprise of 22.66%, on average. ANI Pharmaceuticals is scheduled to report third-quarter results on Nov. 7.
Vertex Pharmaceuticals (VRTX - Free Report) has an Earnings ESP of +0.57% and a Zacks Rank #3.
Vertex’s stock has risen 4.3% so far this year. VRTX beat earnings estimates in two of the last four reported quarters while missing the same on the remaining two occasions, delivering an earnings surprise of 2.15%, on average. Vertex is scheduled to report third-quarter results on Nov. 3.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Rigel Gears Up to Report Q3 Earnings: Here's What to Expect
Key Takeaways
Rigel Pharmaceuticals (RIGL - Free Report) is scheduled to report third-quarter 2025 results on Nov. 4, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $61.6 million, while the same for earnings is 93 cents per share.
Let’s see how things might have shaped up before the announcement.
Factors Shaping RIGL's Q3 Results
Rigel records revenues primarily from the sale of its marketed products and contract revenues from collaborations.
The majority of the company’s revenue growth in the third quarter is likely to have been driven by the robust uptake of its lead product, Tavalisse, which is approved for treating chronic immune thrombocytopenia (“ITP”).
Tavalisse sales are being driven by continued strong new patient demand and the momentum is expected to have continued in the third quarter.
Besides Tavalisse, Rigel is also making good progress with its other marketed products, Rezlidhia (olutasidenib) and Gavreto (pralsetinib), which are approved for treating certain cancer indications. Incremental sales from both these drugs are likely to have boosted Rigel’s top line in the to-be-reported quarter.
Year to date, shares of Rigel have surged 88% compared with the industry’s rise of 7.3%.
Image Source: Zacks Investment Research
Rigel has R289 in its pipeline, a novel dual IRAK1 and IRAK4 inhibitor, in an early-stage study for treating patients with lower-risk myelodysplastic syndrome (MDS). The company is also exploring Rezlidhia’s (olutasidenib) use beyond the approved indication of relapsed or refractory IDH1-mutated AML into other cancers with IDH1 mutations, such as recurrent glioma. Updates related to these activities are expected on the upcoming earnings call.
Higher research and development expenses, as well as increased selling and general and administrative costs, are likely to have escalated operating expenses in the third quarter.
RIGL’s Earnings Surprise History
Rigel has an encouraging history of earnings surprises. The company beat on earnings in each of the trailing four quarters, delivering an average surprise of 1,840.49%. In the last reported quarter, RIGL delivered an earnings surprise of 66.50%.
What Our Model Predicts for RIGL
Our proven model does not conclusively predict an earnings beat for Rigel this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here.
Earnings ESP: Rigel’s Earnings ESP is 0.00%, as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at 93 cents per share. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Rigel has a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Rigel Pharmaceuticals, Inc. Price and EPS Surprise
Rigel Pharmaceuticals, Inc. price-eps-surprise | Rigel Pharmaceuticals, Inc. Quote
Stocks to Consider
Here are some drug/biotech stocks that have the right combination of elements to beat on earnings this time around:
Exact Sciences (EXAS - Free Report) has an Earnings ESP of +20.00% and sports a Zacks Rank #1 at present.
Shares of EXAS have increased 12.5% year to date. EXAS beat on earnings in three of the trailing four quarters and missed in one, delivering an average surprise of 329.87%. Exact Sciences is scheduled to report third-quarter results on Nov. 3.
ANI Pharmaceuticals (ANIP - Free Report) has an Earnings ESP of +10.55% and a Zacks Rank #2.
ANI Pharmaceuticals’ stock has risen 66.3% so far this year. ANIP beat earnings estimates in each of the last four reported quarters, delivering an earnings surprise of 22.66%, on average. ANI Pharmaceuticals is scheduled to report third-quarter results on Nov. 7.
Vertex Pharmaceuticals (VRTX - Free Report) has an Earnings ESP of +0.57% and a Zacks Rank #3.
Vertex’s stock has risen 4.3% so far this year. VRTX beat earnings estimates in two of the last four reported quarters while missing the same on the remaining two occasions, delivering an earnings surprise of 2.15%, on average. Vertex is scheduled to report third-quarter results on Nov. 3.